To the problem of thrombus-hemorrhagic complications in chronic myeloproliferative neoplasias. Complicated diagnosis. Clinical case conference.
Disturbances in the system of hemostasis and vascular complications is the topical clinical problem, requiring profound study with the development of treatment and prophylaxis algorithm. Thrombus-hemorrhagic complications in patients with chronic myeloproliferative (CMPN) neoplasias are caused by the presence of plethoric and myeloproliferative syndromes, findings of hemogram (level of erythrocytes, thrombocytes, leukocytes, hematocrit index) and hemostasiogram testify to this. A case of thrombus-hemorrhagic complication in a female patient with chronic myeloproliferative neoplasia was considered. Carrying out differential diagnostics requires performing additional investigations: USI, CT with defining of hemostasiogram, hemogram findings, their thorough monitoring when surgical intervention is needed. This diagnosis for the first time was made in conditions of surgical in – patient unit. In pre- and postoperative periods as well as for prevention of vascular complicatients in the patient with CMPN it is necessary to mandarory administer agents which correct hematologic status and rheologic indices. This clinical case was analyzed with the aim to draw doctors’ aftention to complexities in diagnostics and defining treatment tactics for patients with thrombus-hemorrhagic complications: necessity to establish all possible risk factors of vascular events development and to carry out constant hemostasiologic menitoring for preventing lethal outcomes.
Abragamovich O, Faynik A, Nechay O. [Mecha-nisms of development of epithelial dysfunction and their role in pathogenesis of ischemia heart disease] Ukr. Kardiol. zhurnal. 2007;4:81-87. Ukrainian. 2. Voznyuk V. [Hemostasis system status and pe-ripheral hemodynamics and vasoregulation features in patients with thrombotic and hemorrhagic complications of polycythemia vera] Ukr. zhurnal gematol. transfuz. 2010;2:5-12. Ukrainian 3. Guseva S, Bessmel’tsev S., Abdulkadyrov K. [Po-lycythemia vera]. K. Logos, 2009;398. Russian. 4. Kostiukevysh O, Mishcheniuk O, Klymenko S. [Assessing significance of peripheral blood indicators for differential diagnosis and prognosis of trombotic com-plications in polycytemia vera and secondary erytro-cytosis]. Medical perspectives, 2014;1:37-44. 5. Pasthernak G. [Thrombosis and embolism pre-vention in adults, children, infants]. Med. Emergency conditions. 2010;6:86-92. Russian. 6. Mc Mullin MF. Idiopathic erytrocytosis: a disap-pearingentity. Hematology Am. Soc. Hematol. Educ. Program. 2009;629-35. 7. Tefferi A. Classification diagnosis and mana-gement of myeloproliferative disorders in the JAK2 V617F. Eur. Hematol. 2006;92:674-7. 8. Teffery A. Polycytemia vera and essential throm-bocythemia; 2012 update on diagnosis, risk stratification and management. Am. J. Hematol. 2012;87:285-93. 9. Kaushansky K, Lichtman M, Beutler E. Williams Hematology. 8th end.-New York: McGraw - Hill Professional. 2010;2304.
GOST Style Citations
This work is licensed under a Creative Commons Attribution 4.0 International License